In a recently released analyst research report, Oppenheimer & Co.‘s Research Analyst, Jay Olson, just reiterated his buy rating on shares of Israeli cannabinoid biotechnology innovator Intec Pharma Ltd. (NASDAQ:NTEC),
This comes just weeks after Ladenburg Thalmann Financial Services Inc. (NYSE:LTS) Managing Director and Senior Biopharmaceuticals Equity Research Analyst, Michael Higgins, reiterated his bullish stance on shares of cannabinoid biotechnology innovator Intec Pharma Ltd. (NASDAQ:NTEC) with a continued buy rating and a price target of $15.00 USD per share.
Higgins’ price target of $15.00 implies a potential upside of approximately 123.54% based on the last traded price of $6.71 USD on the NASDAQ.
Why Olson is Bullish on Intec Pharma
While we can’t say why Olson like Intec Pharma for sure, according to Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma,
“[Intec] entered 2019 on strong footing and expect to build on that momentum throughout the balance of the year as we seek to monetize our late-stage asset in Parkinson’s disease and invest in expanding the clinical development pipeline for our Accordion Pill platform in underserved medical indications with large market opportunities. We believe this two-pronged strategy offers the most attractive opportunities for both near- and long-term value creation.”
Be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from MJobserver.com